Bone Marrow Aspirate Concentrate Is More Effective Than Hyaluronic Acid and Autologous Conditioned Serum in the Treatment of Knee Osteoarthritis: A Retrospective Study of 505 Consecutive Patients

• Published in: Applied sciences Vol. 11; no. 7; p. 2932
• Main Authors: Hussein, Mohsen, van Eck, Carola F., Kregar Velikonja, Nevenka
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-04-2021
• Subjects: Age; Arthritis; Autografts; autologous conditioned serum; Biomedical materials; Bone marrow; bone marrow aspirate concentrate; Cartilage; Cartilage diseases; clinical outcome; Demographics; Demography; Disease; Hyaluronic acid; Knee; Magnetic resonance imaging; Orthopedics; Osteoarthritis; Pain; Patients; Radiographs; Radiography; Standard deviation; Statistical analysis; Stem cells; Variance analysis; Switzerland
• ISSN: 2076-3417; 2076-3417
• DOI: 10.3390/app11072932

The aim of this study was to evaluate and compare the effectiveness of three different intra-articular injective treatments: hyaluronic acid (HA), autologous conditioned serum (ACS) and bone marrow aspirate concentrate (BMAC) for the treatment of knee osteoarthritis (OA). A Level III retrospective comparative clinical study was performed on 505 consecutive patients treated with HA (n = 171), ACS (n = 222) or BMAC (n = 112) for knee OA. The mean patient age was 52 ± 13 years; 54.5% were males. Collected data included patient demographics, symptoms, visual analogue scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and radiographic classification of osteoarthritis grade using plain radiographs and advanced imaging. Clinical outcome was assessed at 3 and 12 months post treatment. Significant improvement in VAS and WOMAC was seen for all three treatments at the 3-month follow-up. At 12 months, VAS was improved in all three treatment groups, yet only BMAC sustained the improved WOMAC even in patients with more severe degenerative changes. This study shows that BMAC is more effective than HA and ACS in the treatment of symptomatic knee OA, especially in the patients with more severe degenerative changes.